Drug profile · INN
everolimus
AFINITOR
everolimus (AFINITOR) is a fk506-binding protein 1a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — everolimus
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 1
- Programs
- 21
- Data quality
- 0.89
Quick answer
everolimus (AFINITOR) is a fk506-binding protein 1a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
FK506-binding protein 1A inhibitor
Primary target: Peptidyl-prolyl cis-trans isomerase FKBP1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is everolimus?
everolimus (AFINITOR) is a fk506-binding protein 1a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for everolimus?
AFINITOR is a marketed brand name for everolimus. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of everolimus?
everolimus has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.